Pharmacogenomic Approaches for Tailored Anti-Leukemic Therapy in Children

Author(s): G. Stocco, R. Franca, F. Verzegnassi, M. Londero, M. Rabusin, G. Decorti

Journal Name: Current Medicinal Chemistry

Volume 20 , Issue 17 , 2013

Become EABM
Become Reviewer


Several lympholytic and cytotoxic agents are used in acute lymphoblastic leukemia (ALL) polychemotherapy. Genetic variants for cellular components involved in the pharmacokinetics and pharmacodynamics of these drugs can influence the pharmacological response, and molecular characterization of these genetic variants could be helpful for the comprehension of the mechanisms of resistance or increased sensitivity. The purpose of this review is to carry out an update of recent publications on genes that might influence ALL treatment in terms of outcome and/or toxicity and to underlie the role of genetic variants, particularly single nucleotide polymorphisms (SNP), in predicting clinical response, with particular reference to the current protocol for ALL therapy used in Italy, AIEOP-BFM ALL 2009.

Keywords: Acute lymphoblastic leukemia, chemotherapy, pharmacogenetics.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [2237 - 2253]
Pages: 17
DOI: 10.2174/0929867311320170008
Price: $65

Article Metrics

PDF: 23